港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

抗疫概念

925.265

-8.623-0.92%

漲家數：2

跌家數：15

平家數：- -

市盈率：- -

高：930.611

開：930.611

低：904.457

收：933.888

成交量：5.37億

成交額：48.20億

市值：6,206.99億

流通市值：5,179.08億

資料載入中...

華昊中天醫藥-B(02563.HK)存倉市值總計8237.50萬港元股東將2500萬股股票存入浦銀國際證券

勁方醫藥-B(02595)：GFH375 兩款全球首創胰腺癌聯合療法邁入II期研究包括RAS靶向藥聯合惡病質雙抗方案及不同作用機制的RAS抑制劑雙聯方案

中國生物製藥有限公司發布新的全球品牌SBP Group，加速國際化佈局

開拓藥業-B(09939)發布中期業績淨虧損7578.2萬元按年減少8.99%

A股晚間熱點 | 抗癌疫苗迎里程碑式突破！Moderna一度狂飆150% 美醫藥股集體引爆

智通财经网

全球首款mRNA腫瘤疫苗三期達標思路迪醫藥(01244)漲17%對標國際獲重估

國藥控股(01099)與國藥集團、國藥股份擬4.06億元出售國瑞藥業合計51%股權

智通财经网

國藥控股擬以2.4億元出售國瑞藥業30.13%股權

鄭亦惟獲批擔任平安健康險審計責任人

石藥集團：SYS6090注射液Ib/Ⅱ期臨床研究已正式啓動

豐展控股(01877.HK)：上海檀英完成減持公司A股股份 2053.37萬股

國藥控股(01099.HK)：國藥股份(600511.SH)上半年歸母淨利潤8.8億元按年減少7.25%

君實生物：上海檀英減持2053萬股套現7.07億元

中國生物製藥(01177)中報觀察：All in AI與全球化雙引擎啓動

智通财经网

中國生物製藥上半年收入194.4億元，按年增長10.6%

《藍籌》中國生物製藥(01177.HK)中期純利34.3億人幣升1.4% 派息7港仙

阿斯达克财经

國藥控股(01099)：國藥器械中期營業利潤5.99億元按年減少12.34%

白雲山(00874)：天心製藥獲得胞磷膽鹼鈉注射液(2ml:0.25g、4ml:0.5g)《藥品補充申請批准通知書》

醫保「十五五」規劃發布疊加重要大會臨近醫藥板塊景氣邏輯有望持續夯實

石藥集團(01093)出現大手賣出210萬股，成交價$8.7，涉資1.827千萬

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BK1515/news?page=14"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":925.2649,"timestamp":1788163726135,"preClose":933.88794,"halted":0,"volume":536532085,"delay":0,"changeRate":-0.009233,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-8.623047,"latestTime":"08-31 16:00:00","open":930.611,"high":930.611,"low":904.4565,"amount":4819960565.96,"amplitude":0.028006,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"pbRate":1.403188,"peRate":17.015388,"turnoverRate":0.006128,"increases":2,"decrements":15,"flats":0,"marketCap":620699252288,"floatMarketCap":517907756096},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":930.611,"amplitude":0.028006,"preClose":933.88794,"low":904.4565,"pbRate":"1.403188","latestPrice":925.2649,"volume":536532085,"delay":0,"open":930.611,"prevYearClose":1190.107,"prevWeekClose":933.888,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":929.009,"twentyDayClose":928.063,"sixtyDayClose":909.52,"secType":"PLATE","market":"HK","turnoverRate":0.006128,"peRate":17.015388,"marketCap":620699252288,"floatMarketCap":517907756096,"timestamp":1788163726135,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":2,"down":15,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:14,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660474989","title":"華昊中天醫藥-B(02563.HK)存倉市值總計8237.50萬港元 股東將2500萬股股票存入浦銀國際證券","url":"https://stock-news.laohu8.com/highlight/detail?id=2660474989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660474989?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 08:29","pubTimestamp":1787185745,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02563","09939","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660471531","title":"勁方醫藥-B(02595)：GFH375 兩款全球首創胰腺癌聯合療法邁入II期研究 包括RAS靶向藥聯合惡病質雙抗方案及不同作用機制的RAS抑制劑雙聯方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2660471531","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660471531?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 08:10","pubTimestamp":1787184633,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，董事会欣然宣布一项GFH375的三臂平行对照II期临床研究已于近期启动。GFH375将进入两款全新联合疗法对照单药治疗的II 期研究，治疗KRAS G12D 突变型经治局部晚期不可切除或转移性胰腺癌患者。KRAS G12D 突变在胰腺癌患者中发生率约40%，同时胰腺癌患者的恶病质发生率居于所有瘤种之首、超过60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","159938","09939","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422810","title":"中國生物製藥有限公司發布新的全球品牌SBP Group，加速國際化佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422810","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422810?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 23:02","pubTimestamp":1787151720,"startTime":"0","endTime":"0","summary":"香港2026年8月19日 /美通社/ -- 中国领先的创新驱动型制药企业中国生物制药有限公司，在中期业绩发布会上宣布推出新的全球品牌SBP Group。统一的品牌形象，体现了公司从国内领先的生物制药企业向全球创新者的战略演进。SBP Group愿联动全球合作伙伴，加速中国创新走向全球、全球创新进入中国的进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5029441_ZH29441_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5029441_ZH29441_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1521","HK0000165453.HKD","BK1589","01177","BK1515","IE00BZ08YT58.USD","BK1191","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660429082","title":"開拓藥業-B(09939)發布中期業績 淨虧損7578.2萬元 按年減少8.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660429082","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660429082?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:38","pubTimestamp":1787150282,"startTime":"0","endTime":"0","summary":"智通财经APP讯，开拓药业-B 发布截至2026年中期业绩，收益由去年同期600万元增至截至2026年6月30日止六个月的5200万元，净亏损7578.2万元，同比减少8.99%;每股亏损0.15元。公司拟动用化妆品销售业务所得现金流量为公司核心产品KX-826及GT20029以及其他管线产品的开发及商业化提供资金。净亏损减少主要由于集团研发成本减少，部分被主要因营销及推广开支增加导致销售及营销开支增加所抵销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660290684","title":"A股晚間熱點 | 抗癌疫苗迎里程碑式突破！Moderna一度狂飆150% 美醫藥股集體引爆","url":"https://stock-news.laohu8.com/highlight/detail?id=2660290684","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660290684?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:32","pubTimestamp":1787149974,"startTime":"0","endTime":"0","summary":"美股医药板块大涨，制药巨头Moderna(莫德纳)一度涨超150%。此外，BioNTech SE涨超17%；默沙东涨超10%，刷新历史新高。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260819/20260819223128_24986.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260819/20260819223128_24986.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02827","159938","83188","09939","BK1574","83130","159646","BK1161","BK1515","159982","399300","02846","03188","07233","82846","BK1147","03130"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660429689","title":"全球首款mRNA腫瘤疫苗三期達標 思路迪醫藥(01244)漲17%對標國際獲重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2660429689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660429689?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:16","pubTimestamp":1787148979,"startTime":"0","endTime":"0","summary":"Moderna与默沙东宣布肿瘤新抗原mRNA疫苗mRNA-4157+K药联合辅助治疗黑色素瘤的三期临床INTerpath-001达到主要终点RFS和关键次要终点DMFS。在港股市场，思路迪医药今日收报2.18港元，大涨17.2%，成为板块情绪的核心受益标的之一。在全球肿瘤免疫治疗迈入基因治疗新纪元的当下，思路迪医药凭借差异化的管线布局与商业化节奏，有望持续获得估值重估的催化剂。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159646","159938","09939","BK1574","01244","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426014","title":"國藥控股(01099)與國藥集團、國藥股份擬4.06億元出售國瑞藥業合計51%股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426014","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660426014?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:05","pubTimestamp":1787148331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股 发布公告，于2026年8月19日，本公司与国药集团、国药股份共同与国药现代订立股权转让协议，据此，本公司同意向国药现代出售本公司持有的目标公司国药集团国瑞药业有限公司30.13%股权，代价为人民币2.4亿元;国药股份同意向国药现代出售其持有的目标公司12.06%股权，代价为人民币9609.3万元;及国药集团同意向国药现代出售其持有的目标公司8.81%股权，代价为人民币7019.73万元。上述合计51%股权的转让代价合计为人民币4.06亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01099","BK0012","BK0250","BK0028","BK0082","BK0097","BK0185","BK1515","LU1115378108.SGD","BK1197","BK0188","600511","BK0175","BK0010","LU0640798160.USD","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165786518","title":"國藥控股擬以2.4億元出售國瑞藥業30.13%股權","url":"https://stock-news.laohu8.com/highlight/detail?id=1165786518","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165786518?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:00","pubTimestamp":1787148010,"startTime":"0","endTime":"0","summary":"国药控股宣布，计划转让其所持有的国药集团国瑞药业有限公司30.13%股权，交易对价高达2.400731亿元人民币。\n这一重大资产处置举措，标志着这家医药巨头正在对其投资组合进行战略性调整。据悉，此次股权出售涉及国药控股在国瑞药业中的相当比例持股，交易金额精确至2.400731亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","BK1500","LU0640798160.USD","LU1115378108.SGD","BK1515","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426999","title":"鄭亦惟獲批擔任平安健康險審計責任人","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426999","media":"金融一线","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660426999?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 21:45","pubTimestamp":1787147100,"startTime":"0","endTime":"0","summary":"8月19日金融一线消息，国家金融监督管理总局发布批复，核准郑亦惟平安健康保险股份有限公司审计责任人的任职资格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/hm/2026-08-19/doc-ininwiee8266398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1615","BK1571","BK1617","01833","BK1219","BK1247","BK1142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660428113","title":"石藥集團：SYS6090注射液Ib/Ⅱ期臨床研究已正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2660428113","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660428113?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 20:11","pubTimestamp":1787141460,"startTime":"0","endTime":"0","summary":"8月19日，石药集团（01093）发布公告，公司开发的SYS6090注射液用于治疗肝细胞癌的Ib/Ⅱ期临床研究已正式启动。该产品注册分类为治疗用生物制品1类，是一种重组全人源抗程序性细胞死亡受体1（PD-1）且融合白介素-15（IL-15）的融合蛋白，可通过其左臂靶向PD-1阳性肿瘤浸润免疫细胞，阻断PD-1和程序性死亡配体1（PD-L1）相互作用导致的免疫抑制功能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846501719.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846501719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0315179316.USD","LU1960683339.HKD","IE00B031HY20.USD","LU0326950275.SGD","LU1226287875.USD","LU1226288253.USD","LU1993786604.SGD","LU0314109678.HKD","01093","LU1813983027.USD","LU2039709279.SGD","BK1521","LU0140636845.USD","IE00BZ08YS42.EUR","LU1807302812.USD","BK1515","IE00BZ08YR35.GBP","LU1328277881.USD","HK0000165453.HKD","LU0880133367.SGD","LU0072913022.USD","LU1152091754.HKD","LU1008478684.HKD","BK1191","IE0008368742.USD","LU1951186391.HKD","LU1226287792.SGD","LU1226288170.HKD","IE0008369823.USD","LU1226287529.USD","LU1152091168.USD","LU0501845795.SGD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE00B543WZ88.USD","KURE","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660642830","title":"豐展控股(01877.HK)：上海檀英完成減持公司A股股份 2053.37萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660642830","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660642830?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 20:01","pubTimestamp":1787140873,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03130","02846","07233","BK1161","02827","BK1148","01877","BK1147","BK1583","03188","BK1515","82846","83130","01826","83188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660447629","title":"國藥控股(01099.HK)：國藥股份(600511.SH)上半年歸母淨利潤8.8億元 按年減少7.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660447629","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660447629?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 19:07","pubTimestamp":1787137633,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1500","LU0640798160.USD","BK1515","BK1197","LU1115378108.SGD","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660100447","title":"君實生物：上海檀英減持2053萬股 套現7.07億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660100447","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660100447?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 19:01","pubTimestamp":1787137260,"startTime":"0","endTime":"0","summary":"8月19日，君实生物（688180/01877）发布公告，股东上海檀英通过大宗交易方式减持2053万股，占公司总股本的2%，减持总金额7.07亿元。2026年一季度，君实生物实现收入7.26亿元，归母净利润-2056万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846440836.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846440836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","BK1515","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448704","title":"中國生物製藥(01177)中報觀察：All in AI與全球化雙引擎啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448704","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660448704?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 17:16","pubTimestamp":1787130988,"startTime":"0","endTime":"0","summary":"中国生物制药正在进入这样一个关键阶段。在安得卫等战略产品的生产中，AI工具在细胞培养监控与纯化风险评估中的应用，助力抗体产量提高20%，生物药制造成本下降20%，直接拉升了产品毛利。其中bepirovirsen有望成为全球首款获批的乙肝功能性治愈药物，其在B-Well系列三期临床中展现出优异的功能性治愈率。纵观2026年中报，中国生物制药正展现出一种“罕见的活力”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["AIPO","BK1589","BK1515","HK0000165453.HKD","VTHR","IE00BZ08YR35.GBP","01177","QTOC","AGIX","IE00BZ08YS42.EUR","ARTY","BK1191","BK1521","CHAT","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498904","title":"中國生物製藥上半年收入194.4億元，按年增長10.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498904","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660498904?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:55","pubTimestamp":1787129700,"startTime":"0","endTime":"0","summary":"8月19日，中国生物制药（01177）发布截至2026年6月30日止6个月的中期业绩公告。报告期内，公司收入194.4亿元，同比增长10.6%；归属于母公司持有者基本溢利33.4亿元，同比增长8.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846321537.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846321537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","BK1521","IE00BZ08YS42.EUR","BK1191","BK1589","IE00BZ08YR35.GBP","BK1515","IE00BZ08YT58.USD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660617446","title":"《藍籌》中國生物製藥(01177.HK)中期純利34.3億人幣升1.4% 派息7港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=2660617446","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660617446?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:51","pubTimestamp":1787129460,"startTime":"0","endTime":"0","summary":"中国生物制药公布2026年6月底止六个月中期业绩，收入194.4亿元人民币(下同)，按年升10.6%。纯利34.3亿元，按年升1.4%；每股盈利19.1分。派中期息7港仙，去年同期派息5港仙。过往派息公布日期派息事项派息内容2026/03/26末期业绩股息：港元 0.0500 2025/08/18中期业绩股息：港元 0.05002025/03/20末期业绩股息：港元 0.0400 2024/08/13中期业绩股息：港元 0.0300期内，非香港财务报告准则指标的基本溢利按年增长8.1%至33.4亿元。创新药及对外授权收入约87.9亿元，按年增长约44.3%，占总收入比例上升至约45.2%。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539305/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539305/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1521","IE00BZ08YT58.USD","01177","HK0000165453.HKD","BK1191","BK1515","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660446843","title":"國藥控股(01099)：國藥器械中期營業利潤5.99億元 按年減少12.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660446843","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660446843?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:50","pubTimestamp":1787129409,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)发布国药器械截至2026年6月30日止六个月业绩，该公司取得营业收入364.92亿元(人民币，下同)，同比增加0.36%;营业利润5.99亿元，同比减少12.34%;归属于母公司所有者的综合收益2.87亿元，同比减少2.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1197","LU0640798160.USD","BK1500","BK1515","01099","LU1115378108.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660445595","title":"白雲山(00874)：天心製藥獲得胞磷膽鹼鈉注射液(2ml:0.25g、4ml:0.5g)《藥品補充申請批准通知書》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660445595","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660445595?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:34","pubTimestamp":1787128449,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)公布，近日，公司控股子公司广州白云山天心制药股份有限公司(以下简称“天心制药”)收到国家药品监督管理局核准签发的胞磷胆碱钠注射液(2ml:0.25g、 4ml:0.5g)《药品补充申请批准通知书》。天心制药本次获得胞磷胆碱钠注射液(2ml:0.25g、4ml:0.5g)《药品补充申请批准通知书》，增加了该药品的规格并通过仿制药质量和疗效一致性评价，有利于提升该产品的市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0175","BK1521","BK0188","BK1197","BK0028","BK1606","BK1515","01477","BK0012","BK0070","BK1574","BK0097","BK1191","00874","BK0196","600332","BK0096","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660443837","title":"醫保「十五五」規劃發布疊加重要大會臨近 醫藥板塊景氣邏輯有望持續夯實","url":"https://stock-news.laohu8.com/highlight/detail?id=2660443837","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660443837?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 15:44","pubTimestamp":1787125498,"startTime":"0","endTime":"0","summary":"A股三大指数今日集体走弱，截止收盘，沪指跌2.40%，收报3894.42点；深证成指跌5.01%，收报13890.15点；创业板指跌6.26%，收报3473.49点。沪深京三市成交额2.53万亿，较昨日放量1103亿。行业板块呈现普跌态势，仅煤炭、银行、房地产服务、航运港口板块逆市上涨，机器人、电子化学品、元件、航天装备、半导体、通信设备、军工电子、消费电子板块跌幅居前。　　国家医保局今天发布《全面医疗保障“十五五”规划》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260819/32339848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1161","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448635","title":"石藥集團(01093)出現大手賣出210萬股，成交價$8.7，涉資1.827千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448635","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660448635?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 15:10","pubTimestamp":1787123400,"startTime":"0","endTime":"0","summary":"[大手成交]石药集团(01093)在下午03:10出现大手卖出，成交量为210万，成交价为港币$8.7，涉资1.827千万。至目前为止，股价跌0.852%，今日最高价为$8.955，而最低价为$8.685，总成交量为4.986千万股，总成交金额港币$4.37亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2608195489/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2608195489/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0880133367.SGD","IE00B5MMRT66.SGD","IE00B031HY20.USD","BK1515","IE00BZ08YT58.USD","LU1152091168.USD","LU1226287875.USD","LU1328277881.USD","KURE","LU0314109678.HKD","LU1226288253.USD","LU1807302812.USD","LU0315179316.USD","LU0326950275.SGD","LU0140636845.USD","LU1226287792.SGD","LU1951186391.HKD","IE00B543WZ88.USD","HK0000165453.HKD","LU1960683339.HKD","IE0008368742.USD","LU1226288170.HKD","01093","LU1993786604.SGD","BK1191","IE00BZ08YR35.GBP","LU1008478684.HKD","LU1152091754.HKD","LU0072913022.USD","LU0501845795.SGD","IE0008369823.USD","BK1521","LU0067412154.USD","LU1226287529.USD","IE00BZ08YS42.EUR","SG9999004220.SGD","LU1813983027.USD","LU2039709279.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":14,"totalSize":301,"code":"91000000","status":"200"}]}}